Induction immunosuppression in liver transplantation: a review.

Published

Journal Article (Review)

Antibody therapy for induction is seldom used in liver transplantation in the United States, but continues to be used in approximately 10% of patients. The most commonly used antibody at the current time is basiliximab (Simulect, Novartis) and is used in adults with renal dysfunction at the time of liver transplantation with the intention of delaying introduction of calcineurin-inhibitors. In children, the same antibody is commonly used in order to reduce rates of acute rejection. Most patients, adult and pediatric, are treated with initially higher levels of tacrolimus rather than antibody induction.

Full Text

Duke Authors

Cited Authors

  • Turner, AP; Knechtle, SJ

Published Date

  • July 2013

Published In

Volume / Issue

  • 26 / 7

Start / End Page

  • 673 - 683

PubMed ID

  • 23651083

Pubmed Central ID

  • 23651083

Electronic International Standard Serial Number (EISSN)

  • 1432-2277

Digital Object Identifier (DOI)

  • 10.1111/tri.12100

Language

  • eng

Conference Location

  • England